What is the recommended emergency department management for a patient presenting with opioid withdrawal?

Emergency Department Management of Opioid Withdrawal

For patients presenting to the ED with moderate to severe opioid withdrawal (COWS >8), administer buprenorphine 4-8 mg sublingually as first-line treatment, as it is superior to nonopioid alternatives and safer than methadone for ED use. 1

Initial Assessment and Timing Confirmation

Confirm adequate time has elapsed since last opioid use to avoid precipitated withdrawal:

• Short-acting opioids (heroin, morphine IR): >12 hours
• Extended-release formulations (OxyContin): >24 hours
• Methadone maintenance patients: >72 hours (consider methadone instead of buprenorphine in these patients) 1

Critical pitfall: Never administer buprenorphine to patients not yet in active withdrawal. Due to its high receptor binding affinity and partial agonist properties, it will precipitate severe withdrawal if given too early. This is especially problematic when transitioning from methadone. 1

Severity Assessment Using COWS

Use the Clinical Opiate Withdrawal Scale (COWS) to objectively measure withdrawal severity:

Mild Withdrawal (COWS <8)

• No buprenorphine indicated
• Reassess patient and COWS in 1-2 hours
• Consider symptomatic management if needed

Moderate to Severe Withdrawal (COWS ≥8)

• Give buprenorphine 4-8 mg SL based on severity
• Reassess after 30-60 minutes
• Target total dose of 16 mg for most patients 1

Treatment Hierarchy

First-Line: Buprenorphine

Buprenorphine is preferred over methadone for ED withdrawal management because methadone's long duration of action (hours to days) extends beyond the ED visit and can interfere with ongoing treatment programs. Additionally, methadone carries overdose risk if patients use additional opioids post-discharge, whereas buprenorphine has a ceiling effect on respiratory depression. 1

Evidence shows buprenorphine produces less severe withdrawal symptoms, fewer adverse effects, and better treatment retention compared to α2-agonists (clonidine/lofexidine). 1

Second-Line: Methadone

Only consider methadone for:

• Patients on methadone maintenance (>72 hours since last dose)
• Settings where buprenorphine is unavailable

Methadone can be administered for up to 72 hours without participation in an opioid treatment program, but is uncommon in many EDs due to safety concerns. 1

Third-Line: Nonopioid Symptomatic Management

Use when opioid-based treatments are contraindicated or unavailable:

• α2-agonists: Clonidine or lofexidine (avoid if hypotensive)
• Antiemetics: Promethazine or ondansetron for nausea/vomiting
• Benzodiazepines: For anxiety, muscle cramps, and catecholamine surge
• Antidiarrheals: Loperamide for diarrhea 1

Prescribing and Legal Considerations

For X-Waivered Providers

Prescribe buprenorphine/naloxone 16 mg SL daily for 3-7 days or until follow-up:

• Sample prescription: Buprenorphine/naloxone 8 mg/2 mg SL tablet/film, take 2 tablets once daily in AM, dispense #6, no refills 1

For Non-X-Waivered Providers

Any DEA-licensed physician can administer (but not prescribe) buprenorphine in the ED with these restrictions:

• Maximum one day's medication at a time
• Treatment cannot exceed 72 hours total
• Must arrange referral for ongoing treatment (provide written referral information) 1

Patients may return for up to 3 consecutive days for interim treatment. 1

Discharge Planning Essentials

Maximize the total buprenorphine dose administered in the ED to improve outcomes and facilitate transition to ongoing care. 1

Mandatory Components

• Addiction treatment referral with specific appointment if possible
• Naloxone kit for overdose prevention
• Overdose prevention education

Strongly Recommended

• Hepatitis C and HIV screening
• Reproductive health counseling 1

Complicating Factors Requiring Modified Approach

Exercise caution or seek consultation for:

• Viable pregnancy
• Chronic opioid therapy for pain
• Anticipated surgery
• Current methadone maintenance
• Intoxication with alcohol, benzodiazepines, or other sedatives
• Post-overdose naloxone reversal
• Serious acute medical illness (heart failure, liver failure, kidney failure, respiratory failure) 1

Emerging Considerations: Xylazine-Adulterated Opioids

Recent drug supply changes with alpha-2 agonist adulterants (xylazine, medetomidine) have complicated withdrawal presentations. While a distinct xylazine withdrawal syndrome remains unclear, standard buprenorphine protocols remain effective. However, MOUD uptake has declined during periods of adulterant emergence, and providers should anticipate more challenging inductions. 2, 3

Why This Approach Reduces Mortality

ED-initiated buprenorphine with linkage to ongoing MOUD reduces all-cause mortality (adjusted HR 0.52; 95% CI 0.42-0.63) compared to no MOUD. 4 This intervention directly addresses the primary outcome of preventing opioid-related deaths while managing the acute distress that drives continued hazardous opioid use. 1